EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiomics‐Based Prognostication in Primary Sclerosing Cholangitis: A Proof‐of‐Concept Study

Laura Cristoferi, Cesare Maino, Davide Paolo Bernasconi, Ilaria Ripamonti, Miki Scaravaglio, Alberto Savino, Eugenia Pesatori, Alessio Gerussi, Eugenia Nofit, Olga Falco, Daphne D'Amato, Francesca Gallivanone und 12 weitere

Liver International · 2025

DOI: 10.1111/liv.70348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Laura Cristoferi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione…. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Magnetic Resonance Imaging, Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian MUR Dipartimento di Eccellenza, Italian MUR PNRR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Risk assessment in primary sclerosing cholangitis (PSC) by magnetic resonance imaging (MRI) relies on semi‐quantitative analysis, which can result in interpretation variability. Radiomics may offer a quantitative approach for risk stratification. This study aims to explore and validate MRI‐derived radiomic features to identify high‐risk PSC patients.

Methods

In this prospective study (January 2019–December 2022), consecutive PSC patients undergoing routine gadoxetate disodium‐enhanced MRI were recruited. Using PyRadiomics, whole liver parenchyma features were extracted from five MRI sequences according to the Image Biomarker Standardisation Initiative (IBSI). Patients were categorised into risk groups based on the Mayo risk score (MRS) and liver stiffness measurement (LSM). Features associated with high‐risk patients were selected and validated in an independent cohort. A survival analysis was conducted in the combined cohort to assess the prognostic value of the radiomic features for clinical events.

Results

One hundred and two PSC patients were enrolled in this study. Five radiomics features were associated with high risk in the training cohort. In the validation setting, GLRLM‐Run Entropy in the fat‐saturation T2 weighted imaging (FS‐T2W) sequence was the only significant feature, with an odds ratio of 3.90 (CI 1.46–10.42, p = 0.007) for MRS and 2.97 (CI 1.33–6.66, p = 0.008) for LSM. Its prognostic potential on clinical outcome was confirmed by Cox regression analysis in the combined cohort (hazard ratio per 0.1 increase = 1.480, CI 1.226–1.786), showing excellent predictive performance (C‐index = 0.857).

Conclusions

GLRLM‐Run Entropy in FS‐T2W is a novel radiomics‐based biomarker for risk stratification in PSC patients. It is quantitative, standardised, easy to compute and cost‐free, positioning it as a potential key innovation in PSC radiology‐based biomarkers. Trial Registration Clinicaltrial.gov ID: NC705618145

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingMagnetic Resonance ImagingLiverHumansFemaleMaleProspective StudiesProof of Concept StudyMiddle AgedAdultPrognosisRisk AssessmentGadolinium DTPAContrast MediaRadiomics

Stichwörter der Autor:innen

artificial intelligenceautoimmune liver diseasesquantitative radiologyradiomicsrisk stratificationsurrogate biomarkers

Substanzen

gadolinium ethoxybenzyl DTPAGadolinium DTPAContrast Media

Autor:innen und Institutionen

  • Division of Gastroenterology, Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Department of Diagnostic Radiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, MB, Italy.
  • Bicocca Bioinformatics Biostatistics and Bioimaging Centre-B4, School of Medicine and Surgery, University of Milan-Bicocca, Monza, MB, Italy.
  • ASST Grande Ospedale Metropolitano Niguarda, Clinical Research and Innovation Unit, Milan, Italy.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Department of Gastroenterology, ASST Papa Giovanni XXIII, Bergamo, Italy.

ORCID-Profile: Luca Saverio Belli, Pietro Invernizzi

Förderung

  • Italian MUR Dipartimento di Eccellenza
  • Italian MUR PNRR

Zitieren

APA

Cristoferi, L., Maino, C., Bernasconi, D. P., Ripamonti, I., Scaravaglio, M., Savino, A., Pesatori, E., Gerussi, A., Nofit, E., Falco, O., D'Amato, D., Gallivanone, F., Alberzoni, C., Viganò, R., Mazzarelli, C., Belli, L. S., Dinelli, M. E., Mutignani, M., Valsecchi, M. G., …, & Bernardi, E. (2025). Radiomics‐Based Prognostication in Primary Sclerosing Cholangitis: A Proof‐of‐Concept Study. Liver International. https://doi.org/10.1111/liv.70348

Vancouver

Cristoferi L, Maino C, Bernasconi DP, Ripamonti I, Scaravaglio M, Savino A, et al. Radiomics‐Based Prognostication in Primary Sclerosing Cholangitis: A Proof‐of‐Concept Study. Liver International. 2025. doi:10.1111/liv.70348

BibTeX
@article{Cristoferi2025,
  author = {Cristoferi, Laura and Maino, Cesare and Bernasconi, Davide Paolo and Ripamonti, Ilaria and Scaravaglio, Miki and Savino, Alberto and Pesatori, Eugenia and Gerussi, Alessio and Nofit, Eugenia and Falco, Olga and D'Amato, Daphne and Gallivanone, Francesca and Alberzoni, Chiara and Viganò, Raffaella and Mazzarelli, Chiara and Belli, Luca Saverio and Dinelli, Marco Emilio and Mutignani, Massimiliano and Valsecchi, Maria Grazia and Corso, Rocco and Invernizzi, Pietro and Carbone, Marco and Ippolito, Davide and Bernardi, Elisabetta De},
  title = {Radiomics‐Based Prognostication in Primary Sclerosing Cholangitis: A Proof‐of‐Concept Study},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70348}
}
Kostenlos starten →